Cervical Ripening prior to First Trimester Termination of pregnancy: Comparitive study between Isosorbide Mononitrate and Misoprostol by Manjula, P
DISSERTATION ON 
CERVICAL RIPENING PRIOR TO FIRST TRIMESTER TERMINATION OF PREGNANCY 
-  COMPARITIVE STUDY BETWEEN ISOSORBIDE MONONITRATE AND 
MISOPROSTOL
THIS DISSERTATION IS SUBMITTED FOR
MD DEGREE EXAMINATION
BRANCH II
OBSTETRICS AND GYNAECOLOGY
STANLEY MEDICAL COLLEGE
CHENNAI – 1.
Submitted to the Tamil Nadu
Dr. MGR MEDICAL UNIVERSITY CHENNAI
MARCH - 2010
ACKNOWLEDGEMENT
I  gratefully  acknowledge and sincerely thank  Dr.A.PRIYA, M.S.,  D.O.  Dean 
Govt. Stanley Medical College Hospital and Dr. S.CHITRA, M.D., PhD., Dean Govt. 
Stanley Medical College, Chennai for granting me permission to utilize the facilities of 
the institution for my study.
I am extremely grateful to our Superintendant, Prof Dr. C.VENI, M.D., D.G.O., 
Dip.NB,  Govt.  R.S.R.M.  Lying  in  Hospital,  Chennai  for  the  guidance  and 
encouragement given in fulfilling my work.
I  express  my  deep  sense  of  gratitude  to  Prof  Dr.  A.KALAICHELVI, 
M.D.D.G.O., Dip.NB., for her valuable guidance at every stage of the study.
I express my sincere thanks to Prof. Dr.AMRITA PRISCILLA NALINI, M.D., 
D.G.O., Prof.  N.HEPHZIBAH  KIRUBAMANI, MD.  D.G.O.,  Ph.D.,  and  Prof. 
T.RUCKMANI, M.D.D.G.O., Department  of  Obstetrics  and  Gynaecology   Govt. 
R.S.R.M. Lying in Hospital for their  guidance   in carrying  out  this  study.
I  am  greatly  indebted  to  Prof  Dr.  G.KARTHIKEYAN  M.D.,  D.M, 
(Cardiology) Head of the Department, Department of Cardiology, Government Stanley 
Medical College and Hospital, Chennai, for giving me permission to do this study.
My  sincere  thanks  to  Dr.  USHA  SADASIVAN,  M.D.,  Ph.D.  Prof.  of 
Pharmacology  Government  Stanley  Medical  College  and  Hospital,  Chennai  for  his 
guidance which helped me to carry out the study successfully.
I am grateful to all our Professors and Assistant professors and my colleagues for 
their help in my research work.
Finally I am extremely thankful to all my patients who cooperated in the study. 
CERTIFICATE
This  is  to  certify  that  the  dissertation  entitled  “DISSERTATION  ON 
CERVICAL RIPENING PRIOR TO FIRST TRIMESTER TERMINATION OF 
PREGNANCY  -   COMPARITIVE  STUDY  BETWEEN  ISOSORBIDE 
MONONITRATE  AND  MISOPROSTOL” is  the  bonafide  original  work  of  Dr. 
P.MANJULA, done by her under my guidance in partial fulfillment of the requirements 
for  MD (Obstetrics  and Gynaecology)  branch II  examination of  The  Tamilnadu Dr. 
M.G.R. Medical University to be held in March 2010. The period of post graduate study 
and training was from May 2007 to February 2010. I forward this to the Tamil Nadu Dr. 
M.G.R. Medical University, Chennai, Tamil Nadu, India.
Prof. Dr. C.VENI, M.D., D.G.O., Dip.NB.,
Professor and Head
Department of Obstetrics and Gynaecology
Govt. Stanley Medical College,
Chennai – 600 001.
The DEAN
Govt. Stanley Medical College,
Chennai – 600 001.
CONTENTS
Sl.No Title Page No.
1. INTRODUCTION 1
2. REVIEW OF LITERATURE 5
3. AIM OF THE STUDY 37
4. MATERIALS & METHODS 38
5. RESULTS & ANALYSIS 44
6. DISCUSSION 62
7. SUMMARY 68
8. CONCLUSION 70
8. PROFORMA
9. BIBLIOGRAPHY
10. MASTER CHART
DISSERTATION ON
CERVICAL RIPENING PRIOR
TO FIRST TRIMESTER TERMINATION OF
 PREGNANCY -  COMPARITIVE STUDY
BETWEEN ISOSORBIDE
MONONITRATE (ISMN) AND MISOPROSTOL 
ROLE OF MEDICAL TERMINATION OF PREGNANCY  IN 
POPULATION CONTROL
In developing country like India can MTP show a decline in population growth?
The answer is “yes”
Induced Abortion has been practiced as a solution for unwanted Pregnancies 
in all countries. Given the desire in developed countries to limit families to 
one or two children and the efficacy of contraception in general use,  it  is 
extremely likely that any normal couple will experience atleast one unwanted 
pregnancy at sometime during their reproductive years. No amount of legal, 
religion or social restriction or lack of access to professional care will stop 
seeking abortions.
It was estimated that in 1995, 80 million unintended pregnancies occurred 
worldwide each year, of which half of this ended in abortion, resulting in a 
worldwide abortion rate of 35, and abortion ratio of 26. 
In  India  in  1995-96,  5,66,500  pregnancies  were  terminated  legally,  but 
illegally terminated abortions are estimated to have been 12 times greater. 
Worldwide induced abortion is third commonest means of fertility control 
next to sterilizations and oral contraceptive pills. 
This MTP effect of population decline could not be seen in the vast rural 
sector since MTP services are not freely available and practice of spacing 
contraceptives is not much used. 
However, abortion is not accepted as a sole method of family planning but its 
place  is  great  as  a  backup  method  and  as  a  resulting  method  for  the 
acceptance of contraception and sterilization.
ROLE OF MTP IN REDUCING MATERNAL MORTALITY DUE TO ILLEGAL 
ABORTIONS
It is estimated that out of 150,000 induced abortions that are carried out in the world 
everyday, one third are performed under unsafe conditions and of these 500 women 
die everyday. The women who turns to a lack-alley abortionists faces a 100-500 times 
greater risk of death. Worldwide approximately 26-31 million legal abortions and 
10-22 million clandestine abortions are performed every year.
The high acceptance of illegal abortions form rural women from quacks is due to easy 
availability, privacy, low cost and non availability of doctors at rural hospitals and 
poor availability of MTP services at primary health centre.
In a study conducted in India, maternal mortality due to abortion was 12%. This can 
be minimized if not completely eliminated by a safe, efficient and caring family 
planning service accessible to all.
REVIEW OF LITERATURE
DEFINITION
Abortion:
Abortion is the termination of pregnancy, either spontaneously or intentionally, before 
the fetus develops sufficiently to survive. By convention, abortion is usually defined 
as pregnancy termination prior to 20 weeks gestation or less than 500g birthweight. 
Definitions vary, however, according to state laws for reporting abortions and fetal 
deaths.
An abortion may be spontaneous or induced. Induced abortion may be legal or illegal.
Induced abortion is the medical or surgical termination before the time of fetal 
viability.
First trimester termination of pregnancy means termination of pregnancy up to 12 wks 
of gestation.
Elective (voluntary) abortion is the interruption of pregnancy before viability at the 
request of the women but not for reasons of impaired mental health or fetal disease. 
Most abortions performed today fall into this category. Approximately one pregnancy 
is electively aborted for every four liver births delivered in the united states (ventura 
and colleagues, 2003). The Executive Board of American college of obstetricians and 
gynecologist (2000) supports the right of women to choose abortion and considers 
this a medical matter between the women and her physician.
INCIDENCE
It is estimated that about 6 million abortions occur annually in India, of which 2 
million are spontaneous and the rest are induced, of the induced abortions, only about 
15% are legal and the rest are performed illegally.
Globally is approximately 46 million abortions performed of which, 26 million take 
place in countries where abortions are legalized.
Almost 60 percent of induced abortions were performed during the first 8 weeks and 
88 percent during the first 12 wks of pregnancy. 20 percent involved women aged 19 
yrs or younger and the majority were younger than 25 yrs. In 1995-96, in India 
abortion rate is 2.7, abortion ratio 2.1. Eastern Europe has the highest abortion rate.
LEGAL STATUS OF ABORTION IN INDIA
The induced abortion may be legal or illegal. There are many countries in the globe 
where the abortion is not yet legalized. In India, the abortion was legalized by 
“Medical termination of pregnancy Act” of 1971 and was implemented from April 
1972, except in Jammu and Kashmir where it came to effect from 1 November 1976). 
Implementing rules and regulations were written in 1971 and revised again in 1975. 
A Registered medical practitioner is qualified to perform an MTP provided,
a) One has assisted atleast 25MTP in an authorized center and having a certificate.
b) One has got six months of house surgeon training in obstetrics and gynecology.
c) One has got diploma or degree in obstetrics and gynecology.
1. Termination can only be terminated on the written consent of the women. Husband’s 
consent is not required.
2. Pregnancy in a minor girl (below the age of 18 yrs) or lunatic cannot be terminated 
without the written consent of the parent or guardian.
3. Termination is permitted up to 20wks of pregnancy. When the pregnancy exceeds 12 
weeks, opinion of two medical practitioners is required.
4. The abortion has to be performed confidentially and to be reported to the director of 
health services of the state in the prescribed form.
A variety of induced abortion services are available in India, They are
1. Government hospitals and centers
2. Municipal hospitals and maternity homes
3. Recognized non-governmental organization
4. Recognized private hospitals, Nursing home and clinics.
The indications for legal abortions are broadly grouped under the following headings.
1. Medical
2. Eugenic
3. Humanitarian
4. Social
MEDICAL OR THERAPEUTIC
To save the life of the mother. 
It is indicated in 
I. Cardiac disease Grade III,and IV with history of decompensation in the 
previous pregnancy or in between the pregnancies. 
II. Chronic Glomerulonephritis 
III. Malignant hypertension 
IV. Cervical and breast malignancy 
V. Diabetes mellitus with retinopathy 
VI. Epilepsy or psychiatric illness with the advice of a psychiatrist.
EUGENIC:
When there is genetic transmission of mental Disease like downs syndrome, neural 
tube anomalies like anencephaly and hereditary and metabolic diseases.
It is also indicated when the fetus is likely to be deformed due to the action of drugs 
or exposure to viral infections or radiation.
HUMANITARIAN:
Pregnancy due to rape and pregnancy in severe mentally retarded mother.
SOCIAL:
According to WHO report, this forms the commonest indication in the present day 
medical practice. Pregnancy is terminated to promote not only physical or mental 
health but also for social well being of the pregnant women and her family.
It is limited to parous women having unplanned pregnancy with low socio economic 
status, pregnancy caused by rape or unwanted pregnancy due to failure of 
contraceptive device.
METHODS OF FIRST TRIMESTER MTP
1. MEDICAL METHODS
 Prostaglandins
 Mifepristone
 Methotrexate
 Epostane
2. SURGICAL METHODS
 Menstrual Regulation 
 Dilatation and suction evacuation.
 Cervical softening prior to dilatation and suction evacuation.
MEDICAL METHODS
PROSTAGLANDINS (PG) : 
There are two types of PGs for medical methods of  abortion (a) misoprostol (b) 
gemeprost.
MISOPROSTOL:
Misoprostol is a synthetic PG analogue, developed in 1991-1992. It is inexpensive 
and stable at room temperature. It is used orally, sublingually and also vaginally.
a) It acts by enhancing uterine contractions and thus helping expulsion of products 
of conception.
b) Causes cervical softening and dilatation.
Misoprostol is not effective when used alone however when this product is used with 
an antiprogesterone, mifepristone (RU486), the combination has been found to be the 
most successful method for inducing abortion.
GEMEPROST :
Gemeprost is a PG2α Dimethl ester vaginal suppository. It is used vaginaly only for 
induction of abortion in combination with mifepristone or misoprostol. It is unstable, 
costlier and not available in India.
MIFEPRISTONE:
Synthetic steroid. Derivative of 19 Nor testosterone. Antiprogesterones are 
compounds that counter act action of progesterone at the receptor Site. Mifepristone 
also known as RU486. Mifepristone is a strong antiprogesterone and 
antiglucocorticoid agent with antiandrogenic antiestrogenic properties. Used in 
pregnancies more than 48 days, the failure rate with mifepristone increases.
COMBINATION OF DRUGS:
The International Planned Parenthood Federation (IPPF) international Medical 
advisory panel (IMAP) has stated that MTP up to 49 days (7 wks) is highly effective 
with mifepristone and misoprostol.
200mg of mifepristone followed 36-48 hours later by
1mg vaginal gemeprost (or)
800 µgm vaginal misoprostol (or)
400mg oral misoprostol up to completion of 9 weeks
METHOTREXATE:
50mg intramuscular or oral followed 5-7 days later by 800µgm vaginal misoprostol. 
(Repeat misoprostol 24 hours later is required)
EPOSTANE :
A progesterone blocking agent is administered in doses of 200mg every 6 hrs for 7 
days.
SURGICAL METHODS
 MENSTRUAL REGULATION
It is the aspiration of the endometrial cavity within 14 days of missed period in a 
previously normal cycle when presence of early pregnancy cannot be diagnosed 
accurately. Menstrual regulation consists of aspiration of the content of the uterine 
cavity by means of the plastic cannula. It has a simple thumb operated pressure 
control value and piston like handle. It is independent of electricity, is portable and 
washable. It has a plastic 50ml syringe capable of creating a vaccum of over 60cm of 
Hg. It can be done as OPD procedure. A paracervical block or sedation alone usually 
suffices.
The occasional complications include failure to evacuate leading to continuation of 
pregnancy, incomplete evacuation, haemorrhage, infection and anesthetic 
complications.
 SUCTION EVACUATION / VACCUM ASPIRATION (VA)
It is the procedure in which products of conception are sucked out from the uterus 
with the help of a cannula fitted to a suction apparatus. Cervix is dilated with a 
specially designed dilators with a guard, until adequate dilatation is achieved to 
permit introduction of the suction cannula of the appropriate size (diameter 
corresponding to the weeks of gestation). A standard negative suction of 65cm of Hg 
is applied and products are aspirated using a suction cannula.
ADVANTAGES:
1. Blood loss is minimal
2. Chances of uterine perforation is less.
COMPLICATIONS :
Compared to other surgical operations, legally induced first trimester termination of 
pregnancy is remarkably safe. The major complication rate being less than 1 in 100 
procedures.
1. UTERINE HEMORRHAGE:
It occurs in 1-4% of cases, although blood transfusions are required only in 0.6 times / 
1000 abortions. Haemorrhage happens more often with advanced gestational age, 
when dilatation and evacuation, performed instead of vaccum aspiration and when 
general anaesthesia is used instead of local anaesthesia. It can be reduced by the 
concominant use of oxytocic drugs, during the procedure and by prior use of 
laminaria tent or drugs.
2. PELVIC INFECTION:
It ranges from 0.1- 1.5%. The incidence can be reduced by prophylactic use of 
antibiotics.
 CERVICAL INJURY :
It occurs in .01 to 1% cases. It happens more with dilatation and evacuation, in 
advanced gestational age and nulliparous women. It can be minimized to a great 
extent by preoperative cervical priming and dilatation.
 UTERINE PERFORATION :
Most dangerous but happens very rarely in 0.1 to 0.28% cases.
Uterine perforation is due to failure to identify a retroverted or retroflexed uterus. 
Observation alone is usually enough for a small perforation and laprotomy is needed 
if symptoms like fever, profuse bleeding per vaginum and signs of peritonitis persists.
 RETAINED PRODUCTS OF CONCEPTION  :
 By performing check curettage following VA incidence can be reduced.
 CONTINUATION OF PREGNANCY : VA fails in 1% cases. Failure is more within 2 
weeks of amenorrhoea.
 MATERNAL MORTALITY AND MORTIDITY :
Morbidity rate is lowest between 7 and 8 weeks of pregnancy, after which the risk of 
complication rises by about 15-30% for each week of delivery.
LONG TERM COMPLICATIONS :
1. Increased chance of future abortions, prematurity, low birth weight infants.
2. Cervical incompetence
3. Slightly increased risk of sterility and ectopic pregnancy.
4. Asherman syndrome
5. Rh-iso immunization
CERVICAL SOFTENING PRIOR TO DILATATION AND SUCTION 
EVACUATION
Priming the cervix with prostaglandin gel or suppository atleast 4 hours earlier helps 
to soften the cervix so that it yields more easily, and undue force is avoided during 
cervical dilatation.
FEATURES OF MEDICAL AND SURGICAL ABORTION
Medical Abortion Surgical Abortion
1. Usually avoids invasive 
procedure
1. invasive procedure
2. Usually avoids anesthesia 2. sedation used if desired 
3. Requires two or more visits 3. usually requires on visit
4. Days to weeks to complete 4. Complete in a predictable 
period.
5. Available during early 
pregnancy
5. Available during early 
pregnancy
6. High success rate ~95% 6. High success rate ~99%
7. Requires follow-up to 7. Does not require follow-up in 
ensure completion of abortion all cases.
8. Requires patient 
participation throughout 
multistep process.
8. Requires participation in a 
single-step process.
ANATOMY OF THE CERVIX
The human cervix is an organ of diverse properties. It is a tubular connective tissue 
structure that has generally been considered as an inert organ playing a passive role in 
labour to the more active body and fundus of the uterus. During pregnancy it is rigid 
and preserves the growing fetus in the uterus. At term it becomes gradually soft, 
effaced and dilated. However it must perform quite different functions in pregnancy 
and labour, the nature and control of which remain an enigma.
The cervix has two openings. The internal os communicating with the uterine cavity 
and the external  os. The length of the cervix is 2.5cm or a little more. The cervical 
canal is spindle shaped. The mucosa is arranged in folds and has the appearance of 
tree trunk with branches known as ‘arbour vitae’.
HISTOLOGY OF THE CERVIX:
The mucosa is lined by high columnar ciliated epithelium. The direction of the cilia is 
downwards towards the external os. The glands are racemose in type, and secrete 
mucus with a high content of fructose.
The cervix is mainly composed of collagen and 10% smooth muscle as opposed to the 
myometrium, which predominantly consists of smooth muscle.
Cervical fibroblasts are characterized by the long ‘dendrites’. Therefore connective 
tissue components, proteolytic enzymes and other factors secreted by the cells 
through the ‘dendrites’ have a relatively short diffusion distance to any point in the 
tissue allowing fast remodulation of the organ.
The cervical connective tissue contains extra cellular matrix which contains both 
fibrillar and non fibrillar components. The fibrillar component includes collagen and 
elastin, proteoglycans, glycoproteins such as fibrinonectin and other proteins while 
the non fibrillar component contains ground substances.
The cervix predominantly composed of type I collagen (66 percent) and type III 
collagen (33 percent). The firmness of the cervix in the nonpregnant state is mainly 
due to the properties of these collagen fibrils, which are bound together in the form of 
bundles. These bundles are inturn embedded in ground substance consisting of 
proteoglycans. Proteoglycans are made of central core of proteins, which are linked to 
glycosaminoglycans, which are repeating disaccharide units composed of hexosamine 
and an uronic acid. Towards term, the glycosaminoglycan concentration of the cervix 
alters and the dermatan and chondroitin sulphates are replaced by hyaluronic acid, 
which is hydrophilic and imbibes water, which destabilizes the collagen, contributing 
to cervical ripening.
Cervical preparation may reduce the complications of uterine perforation and cervical 
injury. In addition, cervical preparation may make the length of the procedure shorter, 
more comfortable for the patient, and easier to perform. For these reasons, the 
guidelines of the Royal College of Obstetricians and Gynaecologists (RCOG) state 
"cervical preparation is beneficial prior to surgical abortion and should be routine if 
the woman is aged less than 18 years of age or at a gestation of more than 10 weeks" 
[RCOG 2004].
Options for cervical preparation include mechanical dilators and pharmacologic 
agents. Mechanical dilators are able to produce wide cervical dilation in a predictable 
fashion. Isaptent, the Nelaton catheter and the vibrodilator were mechanical dilators 
used in the past [Khanna 1980, Manabe 1981, Ng 1973]. More current methods of 
mechanical dilation include laminaria, Lamicel ®, and Dilapan-S TM. Pharmacologic 
agents such as misoprostol, gemeprost, mifepristone, sodium nitroprusside, soften the 
cervix and allow for easier, less forceful cervical dilation.
 
The ripening of the cervix resulted in softening, effacement and dispensability 
brought about by alterations in the biomechanical properties of the cervical tissue.
There are
a) Reduction in  collagen concentration
b) Increase in water content
c) Change in glycosaminoglycans.
AGENTS USED FOR CERVICAL RIPENING PRIOR TO FIRST 
TRIMESTER TERMINATION OF PREGNANCY
Cervical priming not only helps is softening and further dilatation of the cervix but 
also reduces the chance of cervical injury and makes the procedure much easier. The 
cervical preparation is done by the use of either laminaria tents or drugs.
LAMINARIA TENT:
Laminaria tents are seaweeds from the stem of laminaria digitata or Japonica available 
in different sizes and are sterilized by keeping them in Jars containing absolute 
alcohol from where they can be used readily.
The tents are introduced 6-12 hrs before the operation and are removed at the time of 
operation. The strongly hygrospic laminaria presumably acts by drawing water from 
proteoglycan complexes causing the complexes to dissociate and thereby allowing 
cervix to soften and dilate.
Synthetic hygroscopic dilators have also been used. Lamicel is a polyvinyl alcohol 
polymer sponge impregnated with anhydrated magnesium sulfate (Nicolaides and co-
workers 1983). 
Dilapan is made of hydrogel polymer and while it was used for sometime, it is not 
available now in the United States. It has been claimed that it ripen the cervix more 
rapidly than dilators made of traditional seaweed. 
The Advantages of Laminaria Test:
It decreases the incidence of cervical injury, hemorrhage and perforation. 
The Disadvantages are :
- Extra time and discomfort caused by insertion
- Hourglass contracture and difficulty of  removal
- Infection
- Expulsion of Laminaria tent
DRUGS
Prostaglandins :
They are 20 carbon hydroxy fatty acid with a cyclopenton ring with side chains. They 
are released from cell membrane phospholipids, by phospholipase A and Cyclo 
Oxygenase (COX) pathway. Cyclooxygenase exist in two forms. Cox-1 and Cox-2, 
Cox-1 is constitutive, Cox-2 is inducible responsible for inflammatory and 
pathological changes.
Prostaglandins causes softening and dilatation of cervix referred to as priming or 
ripening. At first it was assumed that prostaglandins induced uterine contractions 
which indirectly dilated the cervix, but now is evident that the prostaglandins 
especially PGE2 alter the structure of connective tissue of the cervix and makes it soft 
and dilated. 
Prostaglandins, particularly PGE2 have a role in the physiological process of cervical 
ripening. 
Mac Isaac and colleagues (1999) randomized women to 400µgm of misoprostol 
placed vaginally 4 hours before first trimester abortion versus laminaria placement. 
Misoprostol effected equal or greater dilatation, causes less pain on insertion and 
produced similar side effects.
Johnston et al (1993) have shown that the administration of PGE2 in late pregnancy 
provokes a rise in circulating levels of chondroitin similar to those observed in 
spontaneous  labour, thereby supporting the concept that PGE2 may induce a 
breakdown of the proteoglycan complex.
Prostaglandins are well established agents for the purpose of cervical ripening in the 
first trimester. The various agents used are,
Gemeprost 1mg
Metenoprost 5mg
Misoprostol 400µg
MISOPROSTOL:
Drug Pharmacology:
PGE1, analogue orally active contains equal amount of two diasteromers presented 
below with their enantiomers indicated by (+:)
Molecular wt : 382.5 C22H3805
Pharmacokinetics :
Misoprostol extensively absorbed both orally and vaginally undergoes rapid 
desertification, to its free acid misoprostalic acid which is responsible for its clinical 
activity and unlike the parent compound is detectable in plasma. The alpha chain 
undergoes beta oxidation and beta chin undergoes omega oxidation followed by 
reduction of Ketone to give PGF analogue.
Tmax – 12 + 3min  (t½ life 20-40 min) serum protein binding is less than 90%
Mechanism of action :
PGs act on their own specific receptors located on cell membrance. Five major types 
of prostanoid receptors have been designated, each after the natural PG for which it 
has greater affinity. All prostanoid receptors are G.protein coupled receptors which 
utilize the IP3/DAG or CAMP transducer mechanisms. Misoprostol binds to EP 
prostanoid receptor. Rapidly absorbed after oral, vaginal and rectal administration. 
With oral administration the half life is less than 30 minutes and peak level is at 15 
minutes. After vaginal administration, there is a gradual rise to a maximum level at 
60-120 minutes, but at 240 minutes (4hrs) the level is still at 60% of peak level.
EFFECTS 
The cyclic Eicosanoids produce a variety of actions depending upon the particular 
PG. PGs differ in their potency to produce a given action and different PGs sometime 
have opposite effects.
SYSTEM EFFECTS
1
.
Gastro Intestinal System Gastric antisecretory agent with 
protective effect on the gastrodeodenal 
muscoa
2
.
Genitourinary & Renal Increase the amplitude and frequency of 
uterine contractions. Stimulates total or 
partial expulsion of uterine contents in 
pregnant women.
3.
Endocrine and Gonadal 
effects
In some patients increases serum 
cortisol concentration.
4
.
Respiratory Effects Reported rare incidence of upper 
respiratory infections, bronchitis, 
bronchospasm, dyspnoea, pneumonia.
5
.
Hepatic There is elevated hepatic enzyme levels.
6
.
Ocular Reports of ocular conjunctivitis is 
documented.
ADVERSE EFFECTS
1
.
Gastro Intestinal System Diarrhoea 15-40%
Pain abdomen 13-20%
2
.
Gynecological           Spotting      0.7%
         Cramps        0.6%
Menstrual disorders   0.3%
Dysmenorrhea          0.1%
Skin :
Few adverse effects like rashes and dermatitis, alopecia noted in few patients.
Musculoskeletal:
Arthralgia, myalgia, back pain in some cases. Very few cases reported infrequently 
with chest pain, diaphoresis, hypertension, hypotension, arrythmias, increase in 
cardiac enzyme level and syncope. 
Prostaglandin causes constriction defects in the distal limbs and facial deformities 
(mobius syndrome), and failure to induce abortion mandates termination of pregnancy 
surgically.
The advantages of prostaglandins are,
(1) it produces more effective cervical ripening
(2) it is more convenient to administer
(3) it can be removed in the event of hyper stimulation.
The contraindications can be classified as absolute and relative.
The absolute contraindications are hypersentivity to prostaglandins. 
The relative contraindications are
1. Asthma
2. Cardiovascular disease
3. Hepatic disease
4. Previous uterine surgery
MIFEPRISTONE ( ANTIPROGESTERONE):
200mg of mifepristone taken orally 46hrs before the procedure, ripens the cervix.
ISOSORBIDE MONONITRATE  : NITRIC OXIDE (NO) DONOR
Organic nitrates and nitrites were introduced into medicine in the 19th century. 
Denitration in the smooth muscle cells release NO which is the main physiological 
vasodilator, normally produced by endothelial cells.
Mode of Action of Nitrates and Nitric oxide:
Both nitrates and nitric oxide activate the soluble guanylate cyclase in vascular 
smooth muscle cells and cause an increase in intracellular cyclic Guanosine 
Monophosphate (GMP) level. This is the 2nd messenger that alters calcium effluxes in 
the cell and induces relaxation.
Pharmacokinetics of Isosorbide Mononitrate:
Pharmacokinetic studies show that isosorbide mononitrate is rapidly absorbed after 
oral administration, reaches peak concentrations within an hour, undergoes no 
significant first-pass metabolism, and is virtually 100% bioavailable. The half-life is 
approximately 5 hours, the volume of distribution is 0.62 liter/kg, and the systemic 
clearance is 115 ml/min.
They are rapidly denitrated by glutathione reductase. The partly denitrated metabolites are less 
active, but have longer t½ s. Rate of absorption from the site of administration and the rate of 
metabolism that govern the duration of action of a particular nitrate.
 The nitric oxide is basically responsible for relaxation of smooth muscles of 
myometrium. This is brought about by formation of NO-GMP from L-Arginine in the 
early pregnancy, excretion of nitrite and C-GMP plasma levels increases thereby 
indicating enhanced formation of NO through the action of Cyclic nitricoxide 
Synthase (CNOS) and L-citrulin and L-arginine. This relaxation of muscles of 
myometrium helps in continuation of pregnancy of till maturity.
NO in early pregnancy is detectable in high concentration and workers like All M 
Yallampalli et al found that in early pregnancy, the myometrial concentration of NO 
increases significantly but in late pregnancy there is reduction of NO in myometrium 
and deciduas.
The formation of NO from L-arginine is part of an intracellular communication 
system. The main target of this widespread system is the intracellular guanylate 
cyclase, which when stimulated produces cGMP from GTP. The dephosthorylation of 
myosin light chain kinesis (MLCK) through a cGMP dependent protein kinase. 
Reduced availability of phosphorylated (active) MLCK interferes with activation of 
myosin. It fails to interacts with actin to cause contraction consequently relaxation 
occurs. 
Advantages of ISMN s
c) It is more stable
d) No first pass metabolism
e) Increased half life and decreased interaction variation.
NO is a free radical with a short half life. It exists in the body for 6 -10 seconds, 
before it reacts with water to form nitrates and nitrites. NO diffuses across cell 
membrane and is synthesized on demand. It is a major chemical messenger in the 
human body, mainly in the central nervous system. Its first discovered function was 
an endothelium derived relaxing factor and a primary regulator of blood pressure. NO 
donors relax the myometrium while inducing cervical ripening.
Tommiska M et al., studied the amount of nitric oxide in cervical fluid samples by 
Griess reaction in pregnant and nonpregnant women after application of misoprostol. 
He found misoprostol induced 4.3 to 5.2 fold elevation in cervical fluid nitric oxide 
concentration in early pregnancy and 4.4 to 18.2 fold elevation in late pregnancy and 
no effect in nonpregnant women. 
No donor induced cervical ripening during pregnancy may be mediated via increased 
prostaglandin F2 α synthesis (Ledingham MA et al, 1999).
Ekerhord E et al (2002) found that analysis of tissue levels of cyclic GMP 
,AMP,COX-1 and 2,PGE2 F2α  on cervical specimen fixed in glutaraldehyde for 
microscopy  in the women scheduled for surgical termination of  first trimester of 
pregnancy with ISMN found increased. On Eletron microscopy changes were similar 
to seen during spontaneous cervical ripening.
De pace V, FACCHINETTI F et al, (2007) found that NO plays a fundamental role 
in human physiology, being involved in the homeostasis of different functions. In 
obstetrics this molecule is determinant in the physiology of labour and cervical 
ripening and etiology of preeclampsia and IUGR.
The NO donor produces effective ripening when applied to guinea pig cervix and it is 
a fundamental mediator of cervical ripening. Thomson Aj et al concluded that the 
NO donor ISMN may provide an alternative for cervical ripening with fewer side 
effects in the first trimester MTP.
The side effects of NO donors administered vaginally has not been described. The 
recognized side effects through other routes includes headache, dizziness, postural 
hypotension, and tachycardia.
OTHER NITRICOXIDE DONORs :
Isosorbide dinitrate, nitroglycerine and glycerol trinitrate. The potent smooth muscle 
relaxants affect the vasculature, gut and uterus. Their tocolytic property showed no 
superiority to other tocolytics (Buhimschi, 2002; clavin; 1996)
NO Donors have important implications for modifying vascular resistance, and thus 
uteroplacental blood flow during pregnancy. (Hull et al., 1994; selingman 1994) 
abnormal synthesis of nitric oxide has been linked to the development of 
preeclampsia (Savvidon and coworkers 2003).
Nitric oxide therapy in term or near term infants with respiratory failure found, the 
nitric oxide significantly  improved oxygenation. (Finer and Barrington 2000).
AIM OF THE STUDY
The aim of the study is
1. To evaluate the effect of intravaginal isosorbide mononitrate for first trimester 
preoperative cervical ripening and to evaluate the maternal side effects if any.
2. To determine the optimum dose required to produce such an effect.
3. To compare the efficacy of intravaginal isosorbide mononitrate with that of 
intravaginal Misoprostol.
MATERIALS AND METHODS
 
            This study was conducted at Department of obstetrics and gynecology, RSRM 
lying in hospital attached to Stanley Medical College. Royapuram. Chennai.
         Study period : The period of study was from July 2008 to Sep 2009.
       Study design : Prospective Study
                              Comparative Study  
1. Number of Patients
200 women who were in good health and who were opting for termination of first 
trimester pregnancies were randomly selected from those who are attending Family 
welfare and antenatal outpatient department were included in the study.
Patients belonging to reproductive age from 18-40 years, with gestational age 
between 8-12 weeks without medical or surgical illness were included, while parity 
and socio economic status not included in the study.
100 patients – Group – I – selected for ISMN Application
100 Patients – Group – II – selected for Misoprostol application
PATIENT SELECTION CRITERIA
INCLUSION CRITERIA   
 18-40 years between 8 to 12 weeks of gestation.
 Irrespective of parity and socio economic status  
EXCLCSION CRITERIA
 Gestational age more than 12 weeks 
 Previous cervical surgery or scarred uterus and cervix
 Severe anemia.
 Significant medical illness such as acute liver disease /cardiovascular disease and 
uncontrolled seizure disorders. 
 Women with adrenal disease or requiring glucocorticoid therapy
 In situ intrauterine device.
Gestational age was estimated by Last Menstrual Period (LMP) and confirmed by 
pelvic examination and sonography.
METHODOLOGY
Written consent of the patients were taken and if the patient was a minor, her parents 
consent was obtained.
50 patients were allotted to G-1A, for whom 40 mg of ISMN kept intravaginaly in the 
posterior fornix 3 hours prior to the dilatation and suction evacuation.
50 patients Group IB in whom 80mg of ISMN kept intravaginaly in the posterior 
fornix 3hours prior to the dilatation and suction evacuation.
100 patients Group II in whom misoprostol 400µg kept intravaginaly in the posterior 
fornix 3 hours prior to dilatation and suction evacuation.
Women were admitted one day prior to the procedure.
History taken. Local Examination (L/E), General Examination (G/E)  Perabdomen (P/
A) and Speculum Examination (S/E) done to rule out cervicitis/ virginitis.
Vaginal examination done and size of the uterus confirmed.
Inj. Tetanus toxoid and prophylactic antibiotics were given. Patients were instructed 
overnight starvation.
INVESTIGATIONS
- Urine Albumin
Sugar
Deposits
- Hemoglobin percentage (Hb%)
- Blood grouping and typing
- Bleeding Time (BT)
- Clotting Time (CT)
-Ultrasound pelvis
INTRAVAGINAL APPLICATION OF ISMN/MISOPROSTOL
Under Strict aseptic precautions, patient in lithotomy position  40 mg or 80mg of 
ISMN or misoprostol 400µg kept in the posterior fornix. 
Patient was monitored for symptoms like,
Nausea
Vomiting
Head ache
Palpitation
Flushing
And  treated if present.
Pulse Rate (PR), Blood Pressure (BP), Temperature monitored every half an hour.
At the end of 3 hours – shifted to Operation Theatre.
TECHNIQUE FOR DILATATION AND SUCTION EVACUATION:
Patient was asked to empty the bladder. An intravenous line (I.V) and one pint of 5% 
dextrose was started. Under I.V. anesthesia patient in lithotomy position with 
antiseptic precautions local parts was painted and draped. Vaginal Examination done. 
Previous finding confirmed. Sims speculum was placed in the posterior vaginal wall 
and anterior cervical lip was visualized and grasped with vulsellum.
The uterine sound was passed, the length of the uterine cavity and position of the 
uterus was noted. Hegar dilator No.8 was introduced through the os and if allowed 
easy passage through the internal os it was classified under nil cervical resistance. If 
further dilatation of the internal os was required once, then it was classified as mild 
cervical resistance and which did not allow No.8 Hegars as severe resistance.
Vaginal bleeding or the intracervical presence of products of conception was 
documented. The largest number of Hegars dilator, which could be introduced 
without difficulty and the ease of mechanical dilatation was assessed.
The products of conception were aspirated using a vacuum aspirator, by introducing 
suction cannula of the appropriate size the products and blood were collected in the 
collecting jar. The Vacuum aspirator is moved over the uterine surface systematically 
in order eventually to cover all the surface of the uterine cavity.
Once this is done a grating sensation is felt all around the uterine cavity, no more 
tissue is aspirated then gentle sharp curettage is done. Methergine 0.2 mg is given 
intramuscularly. Bleeding is checked. Bimanual examination is repeated so as to be 
sure that the uterus is hard and smaller in size than before the procedure. After the 
procedure is over, the patients were placed in dorsal position and vital signs were 
recorded.
Patients were shifted to the observation room and vital signs like pulse, blood 
pressure and temperature were recorded every 15 minutes for first 1 hour and later 
every 30 minutes for 3 hours. Post operative complications like vomiting, headache, 
bleeding per vaginum and hypotension if present were recorded for future analysis 
and treated accordingly.
Patients were shifted to the family welfare ward after 3 hours. 
Non immunized Rh-negative mothers were given 50 µg of anti-D immunoglobulin.
RESULTS AND ANALYSIS
200 cases opting for first trimester abortion were divided into
1) Group I A – pretreated with 40mg of ISMN (n50)
2) Group I B – pretreated with 80mg of ISMN.(n50)
3) Group III – pretreated with misoprostol(n100)
1. DISTRIBUTION OF AGE :
Table :1
Ag
e 
gro
up
Group I 
A
Group I 
B
Group II Total
No % No % No % No %
18-
20
8
16
%
12
24
%
24
24
%
44
22
%
21-
25
22
44
%
20
40
%
64
64
%
10
6
53
%
26-
30
14
28
%
14
28
%
8
8
%
36
18
%
31-
40
6
12
%
4
8
%
4
4
%
14 7%
    In Group IA 72% and Group IB 68% and Group II 72% were in the age group of 
21-30 years.  10% in Group I, 4% in Group II were in the age group of 31-40 years.
1. DISTRIBUTION OF AGE 
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2. DISTRIBUTION OF PARITY:
Table :2
Gravid
a
Group I 
A
Group I 
B
Group II Total
N
o
%
N
o
%
N
o
%
N
o
%
Unmarr
ied
2
4
%
2
4
%
  
4
4
%
8
4
%
1 6
12
%
4
8
%
8
8
%
 1
8
9
%
2 10
20
%
14
28
%
44
44
%
68
34
%
3 28
56
%
30
60
%
44
44
%
10
2
51
%
4 6
12
%
- - 4
4
%
10
5
%
5 - - 2
4
%
- - 2
1
%
    Group IA 76% and Group IB 88% and Group II 88% belongs to Gravida II and III.
2. DISTRIBUTION OF PARITY:
0%
10%
20%
30%
40%
50%
60%
% % %
Group I A Group I B Group II
Unmarried 1 2 3 4 5
3. GESTATIONAL AGE (GA) OF THE RESPONDERS:
Table :3
GA
Group I 
A
Group I 
B
Group II Total
N
o
%
N
o
%
N
o
%
N
o
%
8-10 Weeks 36
72
%
36
72
%
64
64
%
13
6
68
%
11-12 Weeks 14
28
%
14
28
%
36
36
%
64
32
%
GA Wise distribution :
Among the 200 cases, the cases were selected such that divided in 2 subsets based on 
GA with between 8-10 weeks and the other with GA between 11-12 weeks.
3. GESTATIONAL AGE OF THE RESPONDERS:
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8-10 WKS 11-12 Wks
SOCIOECONOMIC STATUS (SES)
SES I II III IV V
76% 16% 8%
Most of them fall into lower socio Economic status. Patients from SES V constituted 
76%,SES IV 16% SES III 8%.
76%
16%
8%
III IV V
4. PREOPERATIVE SIDE EFFECTS OF THE PATIENTS
Table :4
Preoperative 
Side Effects
Group I 
A
Group I 
B
Group II Total
N
o
%
N
o
%
N
o
%
N
o
%
Headache 2
4
%
6
12
%
- - 8
4
%
Abdominal pain - - - - 30
30
%
30
15
%
Bleeding per 
vaginum
- - - - 20
20
%
20
10
%
Fever - - - - 8
8
%
8
4
%
Loose stools - - - - 12
12
%
12
6
%
Dizziness - - - - - - - -
Nausea and 
Vomiting
- - - - 2
2
%
2 1
The patients in group IA & group IB had no specific complaints except for headache 
constitute 8% compared to Group II where 30% had abdominal pain, 20% had 
bleeding per vaginum, 8% had fever, 12% had loose stools, 2% had nausea and 
vomiting, with a significant p value of <0.001.
4. PREOPERATIVE SIDE EFFECTS OF THE PATIENTS 
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5. CERVICAL RESISTANCE OF THE RESPONDERS:
Cervical 
Resistance
Group I 
A
Group I 
B
Group II Total
N
o
%
N
o
%
N
o
%
N
o
%
Nil 40
80
%
44
88
%
94
94
%
17
8
89
%
Mild 10
20
%
6
12
%
6
6
%
22
11
%
Severe - - - - - - - -
In Group IA 20% required further dilatation, in Group IB 12% required further 
dilatation, with a insignificant p value of 0.157 between Group I A and I B
In Group II 94% did not require further dilatation.
Group IA & IB 16% and in Group II 6% required further dilatation with a significant 
P value of .0330.
5. CERVICAL RESISTANCE OF THE RESPONDERS:
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
% % %
Group I A Group I B Group II
Nil MILD Severe
CERVICAL DILATATION
Cervical 
Dilatation(mm)
Group I 
A
Group I 
B
Group II Total
N
o
%
N
o
%
N
o
%
N
o
%
8 24
48
%
12
24
%
6
6
%
42
21
%
10 20
40
%
26
52
%
46
46
%
92
46
%
12 6
12
%
12
24
%
48
48
%
66
33
%
    In Group II patients had 12 mm dilatation in 48% of the cases,but only 18% in 
Group I had 12 mm dilatation with a significant p value of <0.001.
CERVICAL DILATATION
0%
10%
20%
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40%
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60%
Group I A Group I B Group II
8mm 10mm 12mm
6. AMOUNT OF BLOOD LOSS
Blood loss in ml
Group I 
A
Group I 
B
Group II Total
N
o
%
N
o
%
N
o
%
N
o
%
<40ml 21
42
%
22
44
%
30
30
%
73
36.
5%
41-50ml 25
50
%
18
36
%
32
32
%
75
37.
5%
51-60ml 4
8
%
10
20
%
36
36
%
50
25
%
>60ml - - - - 2
2
%
2 1%
In Group IA 42%, Group IB 44% had blood loss of                         < 40 ml. 
In Group II 36 patients had 51-60ml blood loss with incidence of 36% and 2% had 
excessive blood loss more than 60 ml.
6. AMOUNT OF BLOOD LOSS
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AMOUNT OF BLOOD LOSS ACCORDING TO GA
GRO
UP
G
A
<40ml 41-50ml 51-60ml >60ML
Group 
I A
8-1
0 
we
eks
2
0
55.
5%
1
6
44.
5%
- - - -
11-
12 
we
eks
1
7.1
4%
9
64.
3%
4
28.
6%
- -
Group 
I B
8-1
0 
we
eks
2
2
61.
1%
1
4
38.
9%
- - - -
11-
12 
we
eks
- - 4
28.
6%
1
0
71.
4%
- -
Group 
II
8-1
0 
we
eks
3
0
46.
8%
2
8
43.
7%
6
9.5
%
- -
11-
12 
we
eks
- - 4
11.
2%
3
0
83.
3%
2
5.
5
%
In Group IA 55.5% and Group IB 61.1% between 8-10 weeks of gestational age had 
blood loss of <40 ml. 
In group II 83.33% had blood loss of 51-60ml, and 5.5% blood loss of >60ml, in 
11-12 weeks of gestational age.
7. POST OPERATIVE SIDE EFFECTS
Post OP 
Complications
Group I 
A
Group I 
B
Group II Total
N
o
%
N
o
%
N
o
%
N
o
%
Headache - - 2
4
%
- - 2
1
%
Vomiting - - - - 10
10
%
10
5
%
Painabdomen - - - - 10
10
%
10
5
%
Fever - - - - - - - -
Hypotension - - - - - - - -
Perforation of 
uterus
- - - - - - - -
Cervical tear - - - - - - - -
Among the 200 cases about 2 patient in Group IB had headache.In Group II 10% 
of the patients experienced pain abdomen and nausea and vomiting, with a significant p 
value of  .00002.
7. POST OPERATIVE SIDE EFFECTS
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DISCUSSION
Cervical ripening before first trimester surgical termination of pregnancy facilitates 
the procedure and reduces operative morbidity. Pharmacological agents commonly 
used for this indications includes laminariatent, and Prostaglandin (PG) analogues. 
Although PG produces more effective cervical ripening, they are associated with 
several adverse effects including abdominal pain, nausea, vomiting and diarrhoea. 
The ideal cervical ripening agent should be effective and easy to administer with a 
low incidence of side effects.
The inflammatory mediator Nitric Oxide (NO) which has been implicated in a wide 
range of physiological process is a fundamental mediator of cervical ripening in 
animals according to Thomson AJ et al. 1997 to 1998.
We have postulated that NO can ripen the cervix before first trimester surgical 
termination of pregnancy by carrying out three groups randomized on 200 patients to 
compare the clinical effects of NO. donor ISMN 40mg & 80mg and the conventional 
misoprostol.
200 women were selected in random for this purpose 100 cases for 1SMN, 100 cases 
for misoprostol. All cases were analyzed under the following headings.
1. Age
2. Parity
3. Socioeconomic status
4. Period of gestation
5. Induction abortion interval
6. Cervical resistance
7. Cervical dilatation
8. Incidence of preoperative and postoperative complications.
AGE
The women studied in this series were in the age group ranging from 18-40 years out 
of which maximum women were in the age group of 21 to 30 years in both the groups 
and they were distributed equally for comparative study.
According to according to study by Vineeta mohindra, vaginal misoprostal for first 
trimester termination the study group was irrespective of the maternal age and 
according to Thomson Aj  et al, (1998) study, the patients were maximum in the age 
group of 21-30 yrs.
Marital Status and Parity:
In the series out of 200 cases 4% in group I and 4% in group II were unmarried 76% 
of the patients were in gravida II and gravida III in Group IA 88% in group IB, 
indicates that some of Gravida III are still ignorant of the facilities available for 
termination of early pregnancy.
Socio Economic and Educational Status:
Most of the cases belong to lower socio economic status and poor educational status. 
This indicates that lower Socio economic status and educational status of people are 
ignorant of the methods of prevention of conception and methods of early termination 
of pregnancy.
Period of Gestation
In our series the cases were equally distributed between the gestational ages of 8-10 
wks and 11-12wks in both groups. 68% belonged to 8-10wks of gestational age. In 
Thomson AJ et al (1997) study, the gestational age was less than 12 wks.
Induction Abortion Interval
In Group I and Group II 3 hours interval between the application of ISMN or 
Misoprostol and surgical termination of pregnancy similar to Thomson et al., and 
Singh et al., and Mohindra et al., study.
Preoperative Side Effects
The side effect profile of NO, administered vaginally has been described. Their 
recognized side effects were noticed when administered by other routes and include 
headache, dizziness, post operative hypotension and tachycardia. No significant 
changes in maternal heart rate or systolic Blood pressure were detected, though 
headache was reported in 8% of study Group I, according to Chen fc study 15% had 
headache and mild hypotension.
In our study 30% had abdominal pain, bleeding pervaginum in 20% and fever, 
Diarrhoea, nauses and vomiting in 8%, 12% and 2% of the cases in Group II 
(Pretreated with misoprostol). According to Radulovic N et al study with 
misoprostol 69% had pain abdomen, 66% had vaginal bleeding ,44% had nausea and 
vomiting and with ISMN 79% had headache. But according to Vineeta Mohindra et 
al study 17.3% had pain abdomen 4.7% had vomiting with misoprostol. An 
accumulation of Nitric Oxide (NO) donor in uterine smooth muscle would be 
expected to relax the myometrium there by keeping to a minimum preoperative 
abdominal pain.
Cervical Resistance :
Pretreatment with ISMN or misoprostol resulted in lower cervical resistance. There 
were no significant differences in the cervical resistance between the two ISMN group 
indicates that the capacity to ripen the Cervix is not dose dependent although we have 
assessed only two doses of the drug. But with misoprostol spontaneous expulsion of 
products of conception were found  and had significantly greater dilatation and 
required less cumulative force than the ISMN group. According to Licf, chan cw 
(2003) study of comparison of ISMN with misoprostol in cervical ripening before 
suction evacuation more than 80% cervical ripening agent acceptable. Here also 80% 
in group IA and 88% in group IB and 94% in group II cervical ripening agent 
acceptable. 
Cervical Dilatation
Though we cannot compare the dilatation produced by ISMN which is only a ripening 
agent with misoprostol which induces ripening and dilatation. Largest number of 
Hegar’s dilator, which could be introduced without difficulty was assessed. Group II 
patients had 12mm dilatation in 48% of the cases, but only 18% in Group I with 
significant p value of .00000
Amount of blood loss
Amount of blood loss during the procedure varied with the gestational age. In Group 
IA 55.5% and Group IB 61.1% between 8-10 wks of gestational age had blood loss of 
<40ml. 
In group II 83.33% had blood loss of 51-60ml, and 5.5% blood loss of >60ml. No 
women in any group required plasma volume expansion, Blood transfusion or 
laparotomy for perforation and no women in this study had a blood loss of greater 
than 500ml. There were concerns that vascular relaxation effect of ISMN might 
increase the operative blood loss during suction evacuation. Thomson et al., did find 
more operative blood loss with nitric oxide donors than with misoprostol. But 
according to Li cf et al., (2003) there were no difference in the operative blood loss 
between ISMN and misoprostol group.
Post Operative Complications:
This study has demonstrated that ISMN has fewer side effect when used to ripen the 
cervix in first trimester of pregnancy. There was headache experienced in 4% of the 
cases in Group I, vomiting and pain abdomen in 10% of the cases, No cases of either 
perforation of uterus nor cervical laceration in the study group. According to 
Mohindra et al., study 3.3% had incomplete abortion, and there was no cases of 
uterine perforation.
 
SUMMARY
The results of the analysis of the study is summed up as follows.
Majority of patients belonging to this study were in the age group 21-30 yrs, (70% in 
group I and 72% in the Group II). The age distribution was almost equal among the 
all groups.
1. 4% in group I and 4% in group II were unmarried. Majority of the women in all 
the groups belonged to II and III gravida. 
2. The distribution of gestational age in all the three groups were same. More than 
half belongs to 8-10weeks of Gestational age, 72% in Group I and 64% in Groupii 
3. Analysis of the preoperative side effects showed absolutely no untoward side 
effect on the mother in Group I except for headache constitutes 8% Group II- 30% 
had pain abdomen, 20% had bleeding per vaginum, 8% had fever, 12% had loose 
stools and 2% had nausea and vomiting.
4. Analysis of the cervical resistance showed, nil cervical resistance in 80% of the 
cases, mild cervical resistance in 20% and 12% in Group IA and IB, doubling the 
dose has been reduced mild resistance by 40%, where as group II showed 6% 
cervical resistance. But spontaneous expulsion of products of conception were 
found in the of misoprostol group only.
5. The study of the Blood loss during the procedure varied with the gestational age.
6. Only minority of the patients in all the three groups had post operative side 
effects, in Group IB 4% had headache and, in Group II 10% of the patients had 
vomiting and abdominal pain.
7. None of the patients belonging to all three groups had major complications like 
perforation of the uterus or cervical laceration.
CONCLUSION
This study reveals that intravaginal ISMN also ripens the cervix and it can be used as 
an agent for preoperative cervical ripening prior to first trimester surgical termination 
of pregnancy, since it fulfills almost all the criteria for an ideal agent like
 Easy availability 
 Non costly
 Ease of administration
 Safety
 No undesirable maternal side effects .
The effect of ISMN is not dose dependent, even 40mg of single intravaginal 
application brings about adequate cervical ripening, increasing the comfort of surgery 
and avoiding the mechanical trauma to the cervix.
On Critical evaluation intravaginal isosorbide mononitrate is more comfortable both 
to the patient and doctor since it has none of the undesirable side effects like bleeding, 
pain abdomen, fever or loose stools when compared with conventional misoprostol.
But compared to misoprostol, ISMN is less effective in cervical ripening but less 
maternal side effects. Spontaneous expulsion of products of conception were found 
only in cases of misoprostol and it produced more pronounced cervical ripening.
To conclude this study reveals that intravaginal ISMN can also be used as an effective 
and safe alternative to misoprostol for cervical ripening prior to first trimester surgical 
termination of pregnancy when indicated avoiding misoprostol induced complications 
.
PROFORMA
NAME AGE IPNO
18-2
0
21-2
5
26-3
0
>30
ADDRESS DOA :
OCCUPATION
SES I  II   III      IV       V
Menstrual History   Last Menstrual Period (LMP)
Expected Date of Delivery (EDD)  
Regular / Irregular
Marital History Married Since
Unmarried
OBSTETRIC CODE:
History of Previous MTP Done
1. At how many weeks
2. Methods adopted
History of Previous scar
Gynecology
Obstetric
History of previous vaginal delivery
Last Child Birth (LCB)
Past History :   Diabetes mellitus, systemic hypertension and 
history of allergies.
Reasons for MTP
Social cause
Delayed diagnosis/failure of contraception
Congenital anomalies
Medical reasons
Unwed pregnancies
General Examination
Anemic Yes/No Temp
Febrile Yes/No PR
          Pedal edema           BP
CVS RR
RS
P/A – Size of Uterus in Weeks
8 10 12
Any Scar
Local Examination 
 Speculum Examination
Pervaginal Examination
INVESTIGATIONS
Urine     Albumin     Hb%
                         Sugar
    Deposits
BloodG & T
BT
CT
Ultrasound pelvis
Time of Application
Dose
Time of MTP
Complaints after administration the drug
1. Vomiting
2. Head ache
3. Giddiness
4. Bleeding
5. Fever
Duration between the administration of the drug & MTP
Dilatation of Cervix
Hegars dilator Size 8         10        12
DURING PROCEDURE
 Resistance
 Need for further dilatation
 Amount of bleeding
 Anaesthetic complication
 Cervical laceration
 Uterine perforation
 Sepsis
RECOVERY PERIOD
COMPLICATIONS:
Vomiting Bleeding
Headache Fever                         Hypotension
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